Telo Genomics Corp. Announces Upsizing of Previously Announced Private Placement

Executive Summary

• Telo Genomics announced an upsizing of its non‑brokered private placement from a maximum of $1.2 M to $1.6 M.
• The offering consists of secured convertible debentures bearing 15% annual interest (compounded quarterly) maturing on Dec 15, 2026, with conversion rights at $0.05 per share and detachable warrants exercisable at $0.08 for up to 12 months.
• Net proceeds (up to $1.6 M total, including the prior tranche of $840 k) will be used for working capital and general corporate purposes; closing of the final tranche is expected on or before March 6, 2026.

Key Details

• Upsized Offering Size: Increased from up to $1,200,000 to up to $1,600,000.
• Debenture Terms:
• Interest rate 15% per annum, compounded quarterly.
• Maturity date December 15, 2026.
• Convertible at holder’s election any time before maturity at a price of $0.05 per share.
• No pre‑payment right for the Company.
• Warrant Terms: For every $100,000 of debentures issued, the Company will issue 2 million detachable warrants.
• Exercise price $0.08 per share.
• Exercisable for a period of 12 months from closing date.
• Prior Tranche: Closed on an initial tranche issuing debentures and 16,800,000 warrants, generating gross proceeds of $840,000.
• Remaining Tranches: Company intends to close one or two additional tranches for aggregate gross proceeds of up to $760,000; final tranche expected on or before March 6, 2026.
• Use of Proceeds: Net proceeds will be applied to working capital and general corporate purposes.
• Finder’s Fees: Company may pay finder’s fees in connection with the upsized offering.
• Regulatory Conditions: Offering subject to statutory hold period of four months and one day, receipt of all required regulatory approvals, including TSX Venture Exchange approval.

Notable Quotes

(No executive quotes were provided in the release.)